| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. | Chief Patient Officer | Common Stock | 1,802 | $17,533 | $9.73 | 18 Jun 2025 | Direct |
| Stoke Therapeutics, Inc. | Chief Patient Officer | Employee Stock Option (Right to Buy) | 72,000 | 17 Feb 2026 | Direct | ||
| Stoke Therapeutics, Inc. | Chief Patient Officer | Restricted Stock Units | 48,000 | 17 Feb 2026 | Direct | ||
| Provention Bio, Inc. | Chief Commercial Officer | Option to Purchase Common Stock | 0 | 27 Apr 2023 | Direct |